Amplification and multiple amplification of EGFR in 37% and 36% of samples, respectively, as well as significantly reduced methylation of this oncogene in GBM (p < 0.001), is accompanied by its increased mRNA expression (p < 0.001). This evidence concerns the gene EGFR and glioblastoma.